Submit to IJERPH Review for IJERPH Propose a Special Issue

Journal Menu

Journal Browser

Dual Disorder Patients: Clinical and Therapeutical Aspects

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of International Journal of Environmental Research and Public Health (ISSN 1660-4601). This special issue belongs to the section "Health Behavior, Chronic Disease and Health Promotion".

Deadline for manuscript submissions: closed (30 September 2018) | Viewed by 20943

Share This Special Issue

Special Issue Editors

Prof. Dr. Icro Maremmani

E-Mail Website
Guest Editor

2nd Psychiatric Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
Interests: clinical aspects and treatment of dual disorder patients; opioid use disorder; heroin use disorder; pain and addiction
Special Issues, Collections and Topics in MDPI journals

Dr. Matteo Pacini

E-Mail Website
Co-Guest Editor

V.P. Dole Research Team, Institute of Behavioural Sciences, Via di Pratale 3, 56121 Pisa, Italy
Interests: substance use disorders; psychiatric comorbidity; alcoholism; bipolar disorder; psychopharmacology
Special Issues, Collections and Topics in MDPI journals

Dr. Angelo Giovanni Icro Maremmani

E-Mail Website
Co-Guest Editor

V.P. Dole Research Team, Institute of Behavioural Sciences, Via di Pratale 3, 56121 Pisa, Italy
Interests: addiction treatment; psychiatry; dual diagnosis; opiate agonists

Special Issue Information

Dear Colleagues,

We are organizing a Special Issue on “Dual Disorder Patients: Clinical and Therapeutic Aspects” in the International Journal of Environmental Research and Public Health. The venue is a peer-reviewed scientific journal that publishes articles and communications in the interdisciplinary area of environmental health sciences and public health. For detailed information on the journal, we refer you to https://www.mdpi.com/journal/ijerph.

Dual Disorder is a term applied to people who have a Substance Use Disorder and another co-occurring mental illness. It is related to interacting neurobiological and environmental factors involved in behaviours of substance and non-substance associated disorders.

Even if it is clear that patients with Substance Use Disorders present frequent psychiatric comorbidity, researchers in this field remain insufficient to prove the existence of clear progression between substance abuse and other mental illnesses.

Patients with mental disorders, including addictions, should have access to a multidisciplinary care model that integrates and coordinates the mental health network and the addiction network, thereby avoiding the so-called “wrong door syndrome”.

The mental/brain disorder model of addictions has yielded to the development of effective preventive measures, treatment interventions, and public health policies. However, the concept of substance use disorders and dual disorders as brain diseases continues to be questioned, possibly because the neurobiological basis of these compulsive behaviours has not been fully explained.

This Special Issue is open to any subject area related to the clinical and therapeutic aspects of Dual Disorder patients. The listed topics suggest just a few of the many possibilities.

Prof. Dr. Icro Maremmani
Dr. Matteo Pacini
Dr. Angelo G. I. Maremmani
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Environmental Research and Public Health is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2500 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

The clinical and therapeutic aspects of personality disorders in addicted patients
Addiction and symptoms of psychopathology
Addiction and psychopathological dimensions
Addiction and personality disorders
Addiction and bipolar spectrum
Substance use among bipolar patients
The clinical and therapeutic aspects of mood disorders in addicted patients
Epidemiology of Dual Disorders
Assessment and evaluation of depression in addicted patients
Primary or secondary nature of co-morbid mood disorder in relation to addiction
Impact of comorbid mood disorders on the natural course of addictions
Addiction and suicide
Addictions and their consequences on mood
The clinical and therapeutic aspects of anxiety disorders in addicted patients
The clinical and therapeutic aspects of psychotic disorders in addicted patients
Stimulants, cannabinoids, hallucinogenic agents and psychotic disorders
Substance use among psychotic patients
The clinical and therapeutic aspects of aggression and violence in addicted patients
The clinical and therapeutic aspects of alcoholism in addicted patients

Published Papers (5 papers)

Download All Papers

Research

Jump to: Other

14 pages, 321 KiB

Open AccessArticle

Frequency and Predictors of Alcohol-Related Outcomes Following Alcohol Residential Rehabilitation Programs: A 12-Month Follow-Up Study

by Elena Fiabane, Lorenza Scotti, Antonella Zambon, Giovanni Vittadini and Ines Giorgi

Int. J. Environ. Res. Public Health 2019, 16(5), 722; https://doi.org/10.3390/ijerph16050722 - 28 Feb 2019

Cited by 5 | Viewed by 3099

Abstract

Excessive use of alcohol has been identified as a major risk factor for diseases, injury conditions and increased mortality. The aims of this study were to estimate the frequency of success (abstinence and no alcohol related hospitalization) at 6- and 12-month follow-up after hospital discharge, and to identify the predictors of success. In 2009, a total of 1040 patients at their first admission in one of the 12 Residential Alcohol Abuse Rehabilitation Units (RAARUs) participating in the CORRAL (COordinamento of Residenzialità Riabilitative ALcologiche) project were included in the study. Several socio-demographic and clinical variables, and the number of treatments’ strategies during the rehabilitation were collected. Information on alcohol abstinence and no alcohol related hospitalization was assessed through a phone interview using a health worker-administered structured questionnaire at six and 12 months after discharge. An inverse probability weighted, repeated measures Poisson regression model with robust variance was applied to estimate the association between patients’ characteristics and the study’s outcomes, accounting for non-responders status. The frequencies of abstinence and non-alcohol related hospitalization were 68.38% and 90.73% at six months, respectively, and 68.65% and 87.6% at 12 months, respectively. Patients that were already abstainers in the month before RAARUs’ admission have an increased probability of being abstainers after discharge (relative risk: RR 1.20, 95% confidence interval: 95%CI 1.08–1.33) and of having an alcohol related hospitalization at 12 months. Subjects undergoing more than four treatment strategies (RR 1.19; 95% CI 1.01–1.40) had a higher abstinence probability and lower probability of no alcohol related hospitalizations after 12 months. Finally, patients with dual diagnosis (co-occurrence of alcohol abuse/dependence and psychiatric disorders) have a decreased probability of not being hospitalized for alcohol-related problems (RR 0.95; 95% CI 0.91–0.99). The results of this study suggest that specific attention should be paid to the intensity of treatment, with particular regard to a multidisciplinary rehabilitation in order to respond to the complexity of alcohol dependent patients. Full article

(This article belongs to the Special Issue Dual Disorder Patients: Clinical and Therapeutical Aspects)

12 pages, 956 KiB

Open AccessArticle

Comorbidity of Symptoms of Alcohol and Cannabis Use Disorders among a Population-Based Sample of Simultaneous Users. Insight from a Network Perspective

by Stéphanie Baggio, Marlène Sapin, Yasser Khazaal, Joseph Studer, Hans Wolff and Gerhard Gmel

Int. J. Environ. Res. Public Health 2018, 15(12), 2893; https://doi.org/10.3390/ijerph15122893 - 17 Dec 2018

Cited by 11 | Viewed by 4849

Abstract

Research into comorbidity of alcohol and cannabis use disorders has resulted in inconsistent findings, especially among simultaneous users, who used alcohol and cannabis together on a single occasion. This study investigated the association of alcohol and cannabis use disorders among simultaneous users using a network perspective, which considers direct relationships between symptoms. We used a subset of simultaneous alcohol and cannabis users driven from the representative population-based sample of young Swiss men cohort study on substance use risk factors (C-SURF) (n = 1559 at baseline and n = 991 at follow-up). Self-reported symptoms of alcohol and cannabis use disorders were collected. Network analyses included network estimation, visualization, and community detection tests. Alcohol and cannabis use symptoms were separated in two distinct clusters, with few paths between them (eleven positive edges at baseline, three at follow-up). Withdrawal symptoms were likely to connect the two disorders at baseline, but not at follow-up. Alcohol and cannabis use disorders appeared as separate disorders among simultaneous users. Our findings mitigated previous findings on the detrimental association between alcohol and cannabis use. Future studies should incorporate network analyses as a means to study comorbidity in other community and clinical samples to confirm our preliminary findings. Full article

(This article belongs to the Special Issue Dual Disorder Patients: Clinical and Therapeutical Aspects)

► Show Figures

Figure 1

10 pages, 334 KiB

Open AccessArticle

Which Psychopathological Syndromes Could Be Associated with the Risk of Suicide among Substance Users?

by Laura Masferrer, Elisenda Escalé-Muntañà, Rafel Malagón, Jordi Cid and Beatriz Caparrós

Int. J. Environ. Res. Public Health 2018, 15(10), 2279; https://doi.org/10.3390/ijerph15102279 - 17 Oct 2018

Cited by 6 | Viewed by 3200

Abstract

Background: Research has shown that suicide is a highly present phenomenon among the drug dependent population. Moreover, individuals with substance use disorder (SUD) present high psychopathological comorbidity. This study aimed to describe which clinical syndromes are linked to the presence of risk of suicide. Methods: The study was based on a consecutive non-probabilistic convenience sample of 196 patients who attended the Public Addiction Center in Girona (Spain). Sociodemographic data, as well as suicide risk and drug related characteristics, were recorded. The risk of suicide was assessed with the Spanish version of “risk of suicide”. Complicated grief was assessed with the Spanish version of the Inventory of Complicated Grief. Clinical syndromes were measured with the Spanish version of MCMI-III. Results: The syndromes most frequently associated with the presence of risk of suicide were complicated grief, major depression and thought disorder. Conclusions: Different psychopathological syndromes were identified in relation to risk of suicide among patients with SUD. The present results highlight the importance of accurately diagnosing those individuals. Full article

(This article belongs to the Special Issue Dual Disorder Patients: Clinical and Therapeutical Aspects)

11 pages, 492 KiB

Open AccessArticle

Impacts of Type D Personality and Depression, Alone and in Combination, on Medication Non-Adherence Following Percutaneous Coronary Intervention

by Youn-Jung Son, Kyounghoon Lee, Donald E. Morisky and Bo-Hwan Kim

Int. J. Environ. Res. Public Health 2018, 15(10), 2226; https://doi.org/10.3390/ijerph15102226 - 11 Oct 2018

Cited by 13 | Viewed by 3088

Abstract

Background: Medication adherence after percutaneous coronary intervention (PCI) is essential to preventing the risk of restenosis. Even though Type D personality and depression have been known to affect medication non-adherence, their combined influence on PCI patients remains unclear. Aim: We aimed to identify how both Type D personality and depression were associated with medication non-adherence for 3 months after successful PCI. Methods: This prospective cohort study included 257 PCI patients, who took 3 or more cardiac medications, at a university hospital. We measured sociodemographic and clinical variables, Type D personality, depression, and medication non-adherence using face-to-face interviews and medical record reviews. Results: The total prevalence of medication non-adherence at the one- and three-month follow-ups was 14% and 16%, respectively. At one month, the prevalence of those with a combination of Type D personality and depression (23.4%) and depression alone (24%) was significantly higher than other groups. At three months, the prevalence of the Type D personality-only group (39.1%) was the highest. Type D personality increased the risk of medication non-adherence 5.089 times at three months, while depression increased it 2.6 times at one month. However, the risk of medication non-adherence was not increased in patients with combined Type D personality and depression. Conclusions: Individual assessments of Type D personality and depression are required. Therefore, psychological interventions focusing on personality and depression are crucial. Longitudinal follow-up studies must explore the interaction or individual impact of Type D personality and depression on medication non-adherence and other negative outcomes. Full article

(This article belongs to the Special Issue Dual Disorder Patients: Clinical and Therapeutical Aspects)

Other

Jump to: Research

26 pages, 399 KiB

Open AccessPerspective

What we have learned from the Methadone Maintenance Treatment of Dual Disorder Heroin Use Disorder patients

by Angelo G.I. Maremmani, Matteo Pacini and Icro Maremmani

Int. J. Environ. Res. Public Health 2019, 16(3), 447; https://doi.org/10.3390/ijerph16030447 - 03 Feb 2019

Cited by 23 | Viewed by 5970

Abstract

Mental Disorders and Heroin Use Disorder (HUD) often co-occur and constitute correlated risk factors that the authors believe are best considered from a unitary perspective. In this article we review and discuss data collected by the V.P. Dole Research Group in Dual Disorder (V.P. Dole DD-RG) patients according to the following six discussion points: (1) Treatment of personality disorders during Methadone Maintenance Treatment (MMT); (2) Treatment of Mood Disorders during MMT; (3) Treatment of Anxiety Disorders during MMT; (4) Treatment of Psychotic Disorders during MMT; (5) Treatment of violence during MMT; (6) Treatment of Alcohol Use Disorder (AUD) during MMT. In treating Mood Disorder in HUD patients, we must bear in mind the interactions (potentiation and side effects) between psychopharmacology, used substances and agonist opioid medications; the use of psychiatric medications as an anti-craving drug, and the possible use of agonist and antagonist opioid medications in treating the other mental disorders. In treating chronic psychosis in HUD patients, we must consider the potentiation and side effects of antipsychotic drugs consequent on HUD treatment, worsening addiction hypophoria and inducing a more severe reward deficiency syndrome (RDS) in hypophoric patients. Violence and AUD during MMT can benefit from adequate dosages of methadone and co-medication with Sodium gamma-hydroxybutyrate (GHB). The experience of our V.P. Dole DD-RG suggests the following: (a) DD is the new paradigm in neuroscience in deepening our understanding of mental health; (b) To successfully treat DD patients a double competence is needed; (c) In managing DD patients priority must be given to Substance Use Disorder (SUD) treatment (stabilizing patients); (d) Antidepressant use is ancillary to SUD treatment; antipsychotic use must be restricted to acute phases; mood stabilizers must be preferred; any use of Benzodiazepines (BDZs) must be avoided. Full article

(This article belongs to the Special Issue Dual Disorder Patients: Clinical and Therapeutical Aspects)

Journal Menu

Journal Browser

Dual Disorder Patients: Clinical and Therapeutical Aspects

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (5 papers)

Research

Other

Further Information

Guidelines

MDPI Initiatives

Follow MDPI